GlassScriptPhysician profile
Herman Kendrith Beebe
NPI 1972942985
$10,213.27
in general payments reported to CMS, 2019-2025
40 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $755 · 2021: $1,286 · 2022: $1,288 · 2023: $1,664 · 2024: $2,498 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,871.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,109.00 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,253.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,057.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $792.37 | 2019-2025 | |
| Amgen INC. | $732.44 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $665.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $596.38 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $281.52 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.76 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $213.83 | 2024 | Voquezna |
| Abbott Laboratories | $207.84 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $203.32 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $199.04 | 2019-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $191.06 | 2019-2025 | Spravato |
| Allergan, INC. | $176.73 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Beebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.